Takeda to Acquire Maverick for ~$525M

 Takeda to Acquire Maverick for ~$525M

Takeda to Acquire Maverick for ~$525M

Shots:

  • Takeda exercised its option to acquire Maverick for up to $525M up front as well as development and regulatory milestones including Takeda’s current equity stake and Maverick debt. The acquisition is expected to finalize in Q1’21
  • The acquisition will expand Takeda’s I-O portfolio with the addition of two development candidates (MVC-101 & MVC-280) and Maverick’s T-cell engagers COBRA platform, specifically designed to target solid tumor
  • The acquisition 2017 collaboration of the companies to develop conditionally active T-cell engager therapies, in which Takeda received an equity stake and an exclusive right to acquire Maverick after 5yrs.

Click here ­to­ read full press release/ article | Ref: Takeda | Image: Maverick

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post